Pinealon
Synthetic Tripeptide | Neuroprotection & Cognitive Enhancement
Pinealon (Glu-Asp-Arg/EDR) is a synthetic tripeptide bioregulator developed in Russia that demonstrates unique DNA-interaction capabilities for neuroprotection and cognitive enhancement. Research suggests benefits for traumatic brain injury recovery, age-related cognitive decline, and cellular aging processes through direct gene expression modulation.
Daily dose
0.2mg
Frequency
Twice daily
Cycle length
20-30 days
Storage
2-8°C
Key benefits
Direct DNA interaction, neuroprotection, cognitive enhancement, excellent safety profile
How it works
Unique tripeptide that penetrates nuclear membranes to directly interact with DNA, modulating gene expression through histone H1.3 binding and MAPK/ERK pathway activation
Dosage protocols
Goal
Neuroprotection
Dose
0.2mg twice daily · Twice daily
Route
Oral
Goal
Cognitive Enhancement
Dose
5mg daily · Once daily
Route
Subcutaneous injection
Goal
Anti-aging Protocol
Dose
0.2mg twice daily · Twice daily for 30 days
Route
Oral with 3-month breaks
Research indications
neuroprotection
cognitive
anti Aging
sleep
Administration
Interactions
Safety notes
Excellent safety profile based on 40+ years of Russian clinical experience with over 15 million patient exposures
Common side effects are minimal: injection site reactions, mild GI discomfort, headache, and fatigue
No serious systemic toxicity or organ-specific damage reported at therapeutic doses
Contraindicated in pregnancy and lactation due to limited safety data in these populations
No documented drug interactions or cytochrome P450 enzyme involvement
Quality sourcing is critical - distinguish between research-grade and pharmaceutical-grade products
Research studies
5xFAD Alzheimer's Mouse Model (2021)
5xFAD mice | 400 μg/kg IP daily | 28 days | Dendritic spine preservation
Prevention of dendritic spine loss in established Alzheimer's model. Significant neuroprotection through MAPK/ERK pathway modulation and reduced neuroinflammation.
View study →Diabetic Rat Model - Spatial Learning (2020)
Diabetic rats | 100 ng/kg optimal dose | 14 days | NMDA receptor expression increased
Dose-response study identifying 100 ng/kg as optimal for spatial learning improvement. Enhanced NMDA receptor expression in hippocampus with neuroplasticity improvements.
View study →Antioxidant System Modulation (2019)
Cell culture and animal models | 50-100 μg daily | 14 days | ROS reduction and cellular protection
Mechanistic study demonstrating antioxidant effects at lower concentrations with cell cycle modulation at higher doses. Concentration-dependent neuroprotective effects confirmed.
View study →Insomnia Clinical Protocol (2018)
45 patients with sleep disorders | 200 μg daily | 7 days | Sleep quality improvement
Short-term protocol showing rapid improvements in sleep onset and quality. Circadian rhythm optimization without dependency or withdrawal effects.
View study →Human Clinical Trial - Post-Traumatic Cerebrasthenia (2015)
72 patients aged 30-74 | 0.2mg twice daily | 20-30 days | Significant cognitive improvement
Landmark human study demonstrating improved memory, reduced headache severity and duration, and enhanced emotional stability compared to 37 controls. Primary endpoint of cognitive function met with statistical significance.
View study →Aging Study - Polymorbidity Patients (2015)
32 patients aged 41-83 | Variable dosing | 30 days | Anabolic effects and biological age improvement
Clinical assessment of biological aging indicators showing significant improvements in multiple biomarkers. Anabolic effects observed with enhanced cellular function markers.
View study →